Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?
Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26006488?dgcid=rss_sd_all
Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26006488?dgcid=rss_sd_all
“Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?.” Clinical Microbiology and Infection.
@article{article40964,
title = {Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26006488?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...